A Microstirring Oral Pill for Improving the Glucose-Lowering Effect of Metformin
Source abstract
Abstract
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia due to persistent insulin resistance, resulting in elevated blood glucose levels. Metformin is the most prescribed oral drug for lowering high blood glucose levels in T2DM patients. However, it is poorly absorbed and has low bioavailability. Here, we introduce magnesium-based microstirrers to a metformin-containing pill matrix to enhance the glucose-lowering effect of metformin. The resulting microstirring pill possesses a built-in mixing capability by creating local fluid transport upon interacting with biological fluid to enable fast pill disintegration and drug release along with accelerated metformin delivery. In vivo glucose tolerance testing using a murine model demonstrates that the metformin microstirring pill significantly improves therapeutic efficacy, lowering blood glucose levels after a meal more rapidly compared to a regular metformin pill without active stirring. As a result, the microstirrers allow for dose sparing, providing effective therapeutic efficacy at a lower drug dosage than passive metformin pills. These encouraging results highlight the versatility of this simple yet elegant microstirring pill technology, which enhances drug absorption after gastrointestinal delivery to improve therapeutic efficacy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Pancreatic function and diabetes · Hydrogels: synthesis, properties, applications · Advanced Sensor and Energy Harvesting Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Nanoengineering and Chemical Engineering, University of California San Diego, La Jolla, California 92093, United States
Department of Pharmacy, Universidad de Concepcion, Concepcion 4070043, Chile
Funding
National Institute of Allergy and Infectious Diseases · Consejo Nacional de Ciencia y Tecnolog?a · King Abdulaziz City for Science and Technology · Universidad de Concepci?n · Defense Threat Reduction Agency · University of California Institute for Mexico and the United States
References (31)
Show source-provided references
1. 10.1016/j.diabres.2021.10911910.1016/j.diabres.2021.109119 ↗
2. World Health Organization. Diabetes, 2022; https://www.who.int/health-topics/diabetes#tab=tab_1 (accessed 2022 December 10).
3. 10.1210/endrev/bnaa02310.1210/endrev/bnaa023 ↗
4. 10.1038/nrendo.2013.25610.1038/nrendo.2013.256 ↗
5. 10.1177/204201882098022510.1177/2042018820980225 ↗
6. 10.3390/ph1406054510.3390/ph14060545 ↗
7. Tadesse S. · 2021
8. 10.2165/11534750-000000000-0000010.2165/11534750-000000000-00000 ↗
9. 10.1186/s12917-021-03016-310.1186/s12917-021-03016-3 ↗
10. 10.1159/00038164310.1159/000381643 ↗
11. 10.1016/j.ijpharm.2020.12011310.1016/j.ijpharm.2020.120113 ↗
12. 10.1016/j.ijpharm.2014.07.01110.1016/j.ijpharm.2014.07.011 ↗
13. 10.1016/j.jconrel.2018.07.00910.1016/j.jconrel.2018.07.009 ↗
14. 10.1016/j.matpr.2019.06.65010.1016/j.matpr.2019.06.650 ↗
15. 10.1126/scirobotics.aam643110.1126/scirobotics.aam6431 ↗
16. 10.1002/advs.20210338410.1002/advs.202103384 ↗
17. 10.1002/adma.20210717710.1002/adma.202107177 ↗
18. 10.1016/j.bioactmat.2021.08.00410.1016/j.bioactmat.2021.08.004 ↗
19. 10.1038/s41563-022-01360-910.1038/s41563-022-01360-9 ↗
20. 10.1039/C2NR32554C10.1039/C2NR32554C ↗
21. 10.1021/la500819r10.1021/la500819r ↗
22. 10.1002/advs.20210038910.1002/advs.202100389 ↗
23. 10.1038/s41467-017-00309-w10.1038/s41467-017-00309-w ↗
24. 10.1021/acs.nanolett.9b0283210.1021/acs.nanolett.9b02832 ↗
25. 10.1021/acsnano.8b0376010.1021/acsnano.8b03760 ↗
26. 10.1038/s41598-019-42531-010.1038/s41598-019-42531-0 ↗
27. 10.1007/s12325-013-0003-x10.1007/s12325-013-0003-x ↗
28. 10.2337/dc14-148010.2337/dc14-1480 ↗
29. Hanefeld M. · Nutr. Metab. Cardiovasc. Dis. · 2002 · 12 · 98
30. 10.1002/anie.20161177410.1002/anie.201611774 ↗
31. 10.4103/0976-0105.17770310.4103/0976-0105.177703 ↗